Ultrasound imaging as a new tool for assessment of respiratory muscle structure and function in patients with Duchenne Muscular Dystrophy

Ultrasound imaging as a new tool for assessment of respiratory muscle structure and function in patients with Duchenne Muscular Dystrophy - RESMUS-DMD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56724

Enrollment

Registered

2024-04-03

Start date

2024-05-06

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne disease Duchenne Muscular Dystrophy

Interventions

None listed

Eligibility

Age

2 Years to 64 Years

Inclusion criteria

Inclusion criteria: Healthy subjects: competent healthy male volunteers. Patients: - Patients with genetically proven Duchenne Muscular Dystrophy who are currently receiving care at Radboudumc. All participants: - Ability to participate and comply with requirements - If >16: willingness and ability to understand nature and content of the study - If 12-16: Parents and participant with willingness and ability to understand nature and content of the study. - If

Exclusion criteria

Exclusion criteria: Healthy volunteers: - Previous or ongoing neuromuscular disorders. - Previous or ongoing pulmonary deficiencies. - Smoking Patients: - Chronic lung, cardiac or liver disease - Additional diagnosed lung disease

Design outcomes

Primary

Measure	Time frame
• Respiratory muscle thickness: Thickness of the diaphragm, accessory inspiratory muscles and expiratory muscles will be examined with ultrasound • Diaphragm excursion: Excursion of the diaphragm will be assessed • Respiratory muscle echogenicity: quantitative muscle ultrasound (QMUS) will assess echogenicity of the diaphragm, accessory inspiratory muscles and expiratory muscles.	—

Secondary

Measure	Time frame
• All participants; Age, length, weight, medication. • Patients: Age at disease onset, age at diagnosis • Pulmonary function testing (PFT): forced vital capacity (FVC), Forced expiratory volume in one second (FEV1), maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP) and sniff nasal inspiratory pressure (SNIP). For patients, the PFT will be assessed by a pediatric rehabilitation doctor. For healthy participants, it will be assessed by a researcher. • Clinical history: A standardized clinical history will be assessed, including documentation of use of steroids and respiratory support, airway infections and degree of scoliosis.	—

Measure

Time frame

• All participants; Age, length, weight, medication. • Patients: Age at disease onset, age at diagnosis • Pulmonary function testing (PFT): forced vital capacity (FVC), Forced expiratory volume in one second (FEV1), maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP) and sniff nasal inspiratory pressure (SNIP). For patients, the PFT will be assessed by a pediatric rehabilitation doctor. For healthy participants, it will be assessed by a researcher. • Clinical history: A standardized clinical history will be assessed, including documentation of use of steroids and respiratory support, airway infections and degree of scoliosis.

—

Countries

Netherlands

Outcome results